Long Focus Capital Management LLC Makes New $28.11 Million Investment in Elevance Health, Inc. $ELV

Long Focus Capital Management LLC acquired a new stake in Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 87,000 shares of the company’s stock, valued at approximately $28,111,000. Elevance Health comprises approximately 0.9% of Long Focus Capital Management LLC’s investment portfolio, making the stock its 26th biggest position.

Other institutional investors have also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC raised its holdings in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares during the last quarter. Physician Wealth Advisors Inc. grew its holdings in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after acquiring an additional 63 shares during the last quarter. Rossby Financial LCC grew its holdings in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the last quarter. Activest Wealth Management increased its position in shares of Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the period. Finally, Motco increased its position in shares of Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after acquiring an additional 77 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

ELV has been the subject of a number of analyst reports. Weiss Ratings lowered shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. TD Cowen restated a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Guggenheim lowered their price target on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Finally, Morgan Stanley reduced their target price on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Price Performance

Shares of NYSE ELV opened at $291.94 on Tuesday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The stock has a market capitalization of $64.43 billion, a P/E ratio of 11.62, a P/E/G ratio of 1.61 and a beta of 0.51. The company’s 50-day moving average is $336.82 and its 200 day moving average is $334.32. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business posted $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.